CSPC Pharmaceutical Group Limited
1093
Rang in aandelen
#1743
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is... CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic of China, across Asia, in the Americas, and throughout Europe. The company structures its business activities into three main divisions: Finished Drugs, Bulk Products, and Functional Food and Other ventures. The company's extensive portfolio of finished drugs encompasses treatments for a wide range of conditions. Key offerings include NBP (available as soft capsules and injections) for acute ischemic stroke, and Oulaining (capsules and injections) addressing mild to moderate memory and cognitive impairments. For neurological disorders, Enxi targets adult idiopathic Parkinson's disease. In oncology, Duomeisu treats lymphoma, multiple myeloma, ovarian and breast cancers, alongside other malignant tumors, while Jinyouli aids in preventing chemotherapy-induced leucopenia and infections, and Keaili is prescribed for breast cancer. Further therapeutic areas covered by CSPC include various infections, with products such as Shuluoke, Nuomoling, Weihong, and Xinweihong. Cardiovascular health is addressed by Xuanning for hypertension and Encun to avert atherosclerotic thrombosis events. Qixiao provides relief for upper respiratory tract infections, and diabetes management is supported by Linmeixin and Shuanglexin. Bone health solutions include Gubang and Gubangjia for postmenopausal osteoporosis. Additionally, Gaoshunsong offers relief for a broad spectrum of inflammatory and pain-related conditions, including arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, lower back pain, sprains, strains, and other soft tissue injuries. Other notable products include Debixin for various types of ulcers and Qimaite for acute and chronic pain management. Beyond finished pharmaceuticals, CSPC also supplies active pharmaceutical ingredients (APIs) like antibiotics, vitamin C, and caffeine. The company further diversifies into functional foods, glucose products, and provides healthcare services. Originally established in 1992, the company initially operated under the name China Pharmaceutical Group Limited before adopting its current designation, CSPC Pharmaceutical Group Limited, in March 2013. Its primary corporate office is situated in Shijiazhuang, within the People's Republic of China.
Aandeelprijs
$1.06
Marktkapitalisatie
$12.14B
Verandering (1 dag)
-3.97%
Verandering (1 jaar)
-2.20%
Land
CN
Handel CSPC Pharmaceutical Group Limited (1093)
Categorie
Healthcare
P/E-ratio voor CSPC Pharmaceutical Group Limited (1093)
P/E-ratio op October 2026 TTM: 10.93
Volgens de meest recente financiële rapporten en aandelenkoers van CSPC Pharmaceutical Group Limited is de huidige P/E-ratio (TTM) 10.93. Eind 2024 had het bedrijf een P/E van 12.73.
Historiek van P/E-ratio voor CSPC Pharmaceutical Group Limited van 2003 tot 2026
P/E-ratio aan het einde van elk jaar
| Jaar | P/E-verhouding | Wijzigen |
|---|---|---|
| 2026 (TTM) | 10.93 | -57.21% |
| 2025 | 25.55 | 100.66% |
| 2024 | 12.73 | -13.19% |
| 2023 | 14.67 | -6.65% |
| 2022 | 15.71 | -14.46% |
| 2021 | 18.37 | -5.49% |
| 2020 | 19.43 | -37.71% |
| 2019 | 31.20 | 41.73% |
| 2018 | 22.01 | -48.49% |
| 2017 | 42.73 | 63.02% |
| 2016 | 26.21 | -21.86% |
| 2015 | 33.55 | -16.97% |
| 2014 | 40.40 | -8.07% |
| 2013 | 43.95 | 2,247.39% |
| 2012 | 1.87 | -73.39% |
| 2011 | 7.04 | -32.64% |
| 2010 | 10.44 | 35.15% |
| 2009 | 7.73 | 58.22% |
| 2008 | 4.88 | -51.33% |
| 2007 | 10.04 | -92.16% |
| 2006 | 128.04 | 1,028.92% |
| 2005 | 11.34 | -6.45% |
| 2004 | 12.12 | 72.98% |
| 2003 | 7.01 | 0.00% |
P/E-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/E-ratio | Verschil in P/E-ratio | Land |
|---|---|---|---|
| 40.53 | 270.68% |
US
|
|
| 38.50 | 252.09% |
US
|
|
| 80.21 | 633.65% |
US
|
|
| 116.96 | 969.71% |
US
|
|
| 22.25 | 103.49% |
CH
|
Hoe lees je een P/E-ratio?
De koers-winstverhouding (P/E Ratio) meet de relatie tussen de aandelenprijs van een bedrijf en de winst per aandeel.
Een lage maar positieve P/E duidt op een bedrijf dat hoge winsten genereert ten opzichte van zijn huidige waardering en mogelijk ondergewaardeerd is. Een bedrijf met een hoge negatieve (dicht bij 0) P/E lijdt grote verliezen.
Bedrijven met een P/E boven 30 of een negatieve waarde worden meestal gezien als "groeiaandelen", wat betekent dat beleggers verwachten dat het bedrijf zal groeien of winstgevend zal worden.
Bedrijven met een positieve P/E onder de 10 worden meestal gezien als "waardeaandelen", wat betekent dat ze al zeer winstgevend zijn, maar weinig groei wordt verwacht.